Targovax Company
Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.
Last Funding Date:
2022-01-12
Last Funding Type:
Grant
Investors Number:
5
Industry:
Peptides and Proteins
Founded Date:
2010-01-01
Total Funding:
30331820
Headquarters:
Oslo, Oslo, Norway
Estimated Revenue:
$1M to $10M
Funding Status:
IPO